SUMMIT: Benefits From Tirzepatide Similar By Sex in Patients With Obesity-Related HFpEF Treatment benefit from tirzepatide was consistent across multiple domains of heart failure (HF) severity and did not differ by sex, despite women exhibiting greater adiposity, symptom severity and poorer exercise capacity but lower left ventricular mass and paracardiac fat deposition when compared to men, according to a secondary analysis of the SUMMIT trial published July 10 in JACC: Heart Failure
Chronic Intermittent Hypoxia-Induced Vascular Dysfunction in Rats is Reverted by N-Acetylcysteine Supplementation and Arginase Inhibition
Contact your healthcare provider if the bad taste is severe or persistent, affects your ability to take medication as prescribed, is accompanied by other concerning symptoms like severe nausea or signs of oral infection, or significantly impacts your quality of life
About a dozen states cover GLP-1s for obesity
The subscription auto-renews, so if you forget to cancel, you will be charged for the next period
